Abstract
Serum cystatin C (CysC) is being promoted by the major nephrology societies as a confirmatory biomarker to estimate glomerular filtration rate (GFR). Many clinicians have the impression that CysC may be a better biomarker for estimating GFR in cancer patients because it is less influenced by muscle mass and nutritional status. Cancer patients were not well represented in the cohorts from which the most frequently used Cr based eGFR estimating equations were derived. Clinical data supports that serum CysC levels are affected by the cancer milieu itself and by clinical factors that are often present in cancer patients. This article highlights data showing that serum CysC levels cannot be reliably used to estimate GFR in solid tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
